Opioid addiction and abuse in primary care practice: A comparison of methadone and buprenorphine as treatment options

Journal of the National Medical Association

Volumn 104, Issue 7-8, 2012, Pages 342-350

  Bonhomme, Jean ^a   Shim, Ruth S ^a   Gooden, Richard ^a   Tyus, Dawn ^a   Rust, George ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Abuse use; Substance

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; ILLICIT DRUG; METHADONE; NALOXONE;

AFRICAN AMERICAN; ANALGESIA; CHRONIC PAIN; CLINICAL PRACTICE; CONSTIPATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG MISUSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; ETHNICITY; HEALTH DISPARITY; HUMAN; LOW DRUG DOSE; MEDICAL EDUCATION; MENTAL HEALTH CARE; META ANALYSIS (TOPIC); OPIATE ADDICTION; PENIS ERECTION; PHYSICIAN; PREGNANCY; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SCREENING; SEXUAL DYSFUNCTION; SIDE EFFECT; SUBSTANCE ABUSE; SWEAT; UNITED STATES; WITHDRAWAL SYNDROME;

EID: 84866847412     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30175-9     Document Type: Article

References (72)

1. Satcher D. Mental Health: Culture, Race, and Ethnicity - A Supplement to Mental Health: A Report of the Surgeon General; 2001.
2. Lillie-Blanton M, Anthony JC, Schuster CR. Probing the meaning of racial/ethnic group comparisons in crack cocaine smoking. JAMA. 1993;269(8):993.
3. Broz D, Ouellet LJ. Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic. Drug Alcohol Depend. 2008;94(1-3):221-233.
4. Strassels SA. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm. 2009;15(7):556.
5. Ruetsch C. Empirical view of opioid dependence. J Manag Care Pharm. 2010;16(1 suppl B):S9.
6. Hatzenbuehler ML, Keyes KM, Narrow WE, et al. Racial/ethnic disparities in service utilization for individuals with co-occurring mental health and substance use disorders in the general population. J Clin Psychiatr. 2008;69(7):1112.
7. Elwy AR, Ranganathan G, Eisen SV. Race-ethnicity and diagnosis as predictors of outpatient service use among treatment initiators. Psychiatr Serv. 2008;59(11):1285.
8. Snowden LR, Pingitore D. Frequency and scope of mental health service delivery to African Americans in primary care. Ment Health Serv Res. 2002;4(3):123-130.
9. Krantz MJ, Mehler PS. Treating opioid dependence: growing implications for primary care. Arch Intern Med. 2004;164(3):277.
10. Magura S. What more do we need to know about medication-assisted treatment for prescription opioid abusers? Addiction (Abingdon, England). 2009;104(5):784.
11. Knudsen HK, Roman PM. Racial and ethnic composition as a correlate of medication availability within addiction treatment organizations. Socio Focus. 2009;42:133.
12. Mental Health Services Administration. Results from the 2004 National Survey on Drug Use and Health: National Findings. Rockville, MD: SAMHSA; 2005. NIDA Notes. 2006;20(6). Office of Applied Studies, NSDUH Series H-28, DHHS publication SMA 05-4062.
13. De Angelis D, Hickman M, Yang S. Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. Am J Epidemiol. 2004;160(10):994.
14. Back SE, Payne RL, Simpson AN, et al. Gender and prescription opioids: Findings from the National Survey on Drug Use and Health. Addict Behav. 2010;35(11):1001-1007.
15. Fleming MF, Davis J, Passik SD. Reported Lifetime Aberrant Drug Taking Behaviors Are Predictive of Current Substance Use and Mental Health Problems in Primary Care Patients. Pain Med. 2008;9(8):1098-1106.
16. Canfield MC, Keller CE, Frydrych LM, et al. Prescription Opioid Use Among Patients Seeking Treatment for Opioid Dependence. J Addict Med. 2010;4(2):108.
17. Porucznik C, Sauer B, Johnson E, et al. Adult use of prescription opioid pain medications-Utah, 2008. MMWR Morb Mortal Wkly Rep. 2010;59:153-157.
18. Boyd C, Teter C, West B, et al. Non-medical use of prescription analgesics: a three-year national longitudinal study. J Addict Dis. 2009;28(3):232-242.
19. Cai R, Crane E, Poneleit K, et al. Emergency Department Visits Involving Nonmedical Use of Selected Prescription Drugs in the United States, 2004-2008. J Pain Palliat Care Pharmacother. 2010;24(3):293-297.
20. Wu LT, Woody GE, Yang C, et al. Subtypes of nonmedical opioid users: Results from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend. 2010;112(1-2):69-80.
21. Haller DL, Acosta MC. Characteristics of pain patients with opioid-use disorder. Psychosomatics. 2010;51(3):257.
22. Babor TF, McRee BG, Kassebaum PA, et al. Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a public health approach to the management of substance abuse. Subst Abuse. 2007;28(3):7.
23. Barrett SP, Meisner JR, Stewart SH. What constitutes prescription drug misuse? Problems and pitfalls of current conceptualizations. Curr Drug Abuse Rev. 2008;1(3):255-262.
24. Jamison RN, Ross EL, Michna E, et al. Substance misuse treatment for high-risk chronic pain patients on opioid therapy: A randomized trial. Pain. 2010;150(3):390-400.
25. Heltsley R, Zichterman A, Black DL, et al. Urine Drug Testing of Chronic Pain Patients. II. Prevalence Patterns of Prescription Opiates and Metabolites. J Anal Toxicol. 2010;34(1):32-38.
26. Smith H, Kirsh K, Passik S. Chronic opioid therapy issues associated with opioid abuse potential. J Opioid Manag. 2009;5(5):287.
27. Mayo Clinic. Prescription drug abuse. www.mayoclinic.com/print/ prescription-drug-abuse/DS01079/METHOD=print&DSECTION=all#. Accessed July 10, 2011.
28. National Institute on Drug Abuse. Preventing and recognizing presccription drug abuse. www.nida.nih.gov/ResearchReports/Prescription/ prescription6.html. Accessed July 10, 2011.
29. Moeller KE, Lee KC, Kissack JC. Urine Drug Screening: Practical Guide for Clinicians; 2008.
30. Blanken P, Hendriks VM, Van Ree JM, et al. Outcome of long term heroin assisted treatment offered to chronic, treatment resistant heroin addicts in the Netherlands. Addiction. 2010;105(2):300-308.
31. Rounsaville BJ, Kosten TR. Treatment for opioid dependence: quality and access. JAMA. 2000;283(10):1337-1339. (Pubitemid 30129804)
32. Gilson AM. The concept of addiction in law and regulatory policy related to pain management: a critical review. Clin J Pain. 2010;26(1):70.
33. Sullivan LE, Fiellin DA. Narrative review: buprenorphine for opioid-dependent patients in office practice. Ann Intern Med. 2008;148(9):662.
34. Resnick RB. Food and Drug Administration Approval of Buprenorphine- Naloxone for Office Treatment of Addiction. Ann Intern Med. 2003;138(4):360. (Pubitemid 36205938)
35. CSAT Buprenorphine Information Center. Physician Waiver Qualifications. http://buprenorphine.samhsa.gov/waiver-qualifications.html. Accessed July 10, 2011.
36. Anstice S, Strike CJ, Brands B. Supervised methadone consumption: Client issues and stigma. Subst Use Misuse. 2009;44(6):794-808.
37. Jaffe JH, O'Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003;70(2):S3-S11. (Pubitemid 36556056)
38. Donaher PA, Welsh C. Managing opioid addiction with buprenorphine. Am Fam Physician. 2006;73(9):1573-1578. (Pubitemid 43807052)
39. Simoens S, Matheson C, Bond C, et al. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. Br J Gen Pract. 2005;55(511):139.
40. Kreek MJ. Methadone Related Opioid Agonist Pharmacotherapy for Heroin Addiction: History, Recent Molecular and Neurochemical Research and Future in Mainstream Medicine. Ann N Y Acad Sci. 2000;909(1):186-216. (Pubitemid 30462040)
41. Zuurmond W, Meert T, Noorduin H. Partial versus full agonists for opioid-mediated analgesia: focus on fentanyl and buprenorphine. Acta Anaesthesiol Belg. 2002;53(3):193-201. (Pubitemid 36187826)
42. Schottenfeld RS, Chawarski MC, Pakes JR, et al. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatr. 2005;162(2):340.
43. Fanello S, Daoud S, Panici J, et al. Addictive behavior after starting buprenorphine maintenance treatment. Presse médicale (Paris, France: 1983). 2006;35(2, pt 1):212.
44. Schottenfeld RS, Pakes JR, Oliveto A, et al. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997;54(8):713.
45. Castells X. Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials. Subst Use Misuse. 2009;44(13):1888-1898.
46. Robinson SE. Buprenorphine-containing treatments: place in the management of opioid addiction. CNS Drugs. 2006;20(9):697-712. (Pubitemid 44373700)
47. Bell J, Trinh L, Butler B, et al. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104(7):1193-1200.
48. Al-Gommer O, George S, Haque S, et al. Sexual dysfunctions in male opiate users: a comparative study of heroin, methadone, and buprenorphine. Addict Disord Treat. 2007;6(3):137.
49. Megarbane B, Hreiche R, Pirnay S, et al. Does high-dose buprenorphine cause respiratory depression?: Possible mechanisms and therapeutic consequences. Toxicol Rev. 2006;25(2):79-85.
50. van Dorp E, Yassen A, Sarton E, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology. 2006;105(1):51.
51. Verrando R, Robaeys G, Matheï C, et al. Methadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use. Acta Gastro Enterologica Belgica. 2005;68(1):81.
52. The National Alliance of Advocated for Buprenorphine Treatment. PCSS Guidance. www.naabt.org/documents/PCSShepatitisBupeLiver.pdf. Accessed July 11, 2011.
53. McCance Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. Am J Addict. 2010;19(1):4-16.
54. Bell JR, Butler B, Lawrance A, et al. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend. 2009;104(1-2):73-77.
55. Substance Abuse and Mental Health Servicies Administration. Diversion and Abuse of Buprenorphine: A Brief Assessment of Emerging Indicators http://buprenorphine.samhsa.gov/Buprenorphine-FinalReport-12.6.06.pdf. Accessed July 11, 2011.
56. Pelissier-Alicot AL, Sastre C, Baillif-Couniou V, et al. Buprenorphine-related deaths: unusual forensic situations. Int J Leg Med. 2010;124(6):647-651.
57. Reed LJ, Glasper A, de Wet CJ, et al. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients? J Clin Psychopharmacol. 2007;27(2):188.
58. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96(1-2):69-78.
59. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-2331.
60. Andrew A, Monte M, Mandell T, et al. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis. 2009;28(3):226-231.
61. Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007;88(1):75-78. (Pubitemid 46400304)
62. Tzschentke TM. Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology. 2002;161(1):1-16. (Pubitemid 34437963)
63. Lee JD, Grossman E, DiRocco D, et al. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2009;24(2):226-232.
64. Sohler NL, Li X, Kunins HV, et al. Home-versus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat. 2010;38(2):153-159.
65. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144(2):127.
66. Barry DT, Irwin KS, Jones ES, et al. Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med. 2009;24(2):218-225.
67. Kim TW, Samet JH, Cheng DM, et al. Primary care quality and addiction severity: a prospective cohort study. Health Serv Res. 2007;42(2):755.
68. Weiss RD, Potter JS, Provost SE, et al. A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): Rationale, design, and methodology. Contemp Clin Trials. 2010;31(2):189-199.
69. Veilleux JC, Colvin PJ, Anderson J, et al. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010;30(2):155-166.
70. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Recovery-Oriented Systems of Care. http://partnersforrecovery.samhsa.gov/rosc.html. Accessed November 2, 2010.
71. Sowers W. Transforming systems of care: The American Association of Community Psychiatrists guidelines for recovery oriented services. Community Ment Health J. 2005;41(6):757-774. (Pubitemid 41674453)
72. Maremmani I, Pani PP, Pacini M, et al. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Subst Abuse Treat. 2007;33(1):91-98. (Pubitemid 350198612)